iBB

Umbilical cord matrix (UCM)-derived mesenchymal stem/stromal cells (MSC) are promising therapeutic candidates for Regenerative Medicine settings. However, given the high cell doses required for clinical applications, the large-scale manufacturing of UCM MSC complying with good manufacturing practices is mandatory. In a study published in the Journal of Tissue Engineering and Regenerative Medicine, a group of researchers from BERG-iBB reported the establishment of an integrated culture platform based on a human platelet lysate supplement for the effective isolation and expansion of UCM MSC, using a xenogeneic-free microcarrier-based system featuring easy scalability. This represents an important advance in obtaining safer and clinically meaningful MSC numbers for clinical translation. Click on title to learn more.